Abstract
Long-term melanoma survival is now attainable with anti-PD-1 regimens. Notably, a subset of patients experience disease progression (PD) during their immunotherapy treatment but still survive >5 years. Factors that contribute to this prolonged survival despite initial PD are of great interest for prognostication and treatment selection.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have